Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Annexon, Inc.

Clinical trials sponsored by Annexon, Inc., explained in plain language.

Annexon, Inc. ANNX NASDAQ

Develops complement-based therapies for autoimmune and neurodegenerative diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Experimental drug ANX005 targets blood cell destruction in autoimmune anemia

Disease control Completed

This phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…

Phase: PHASE2 • Sponsor: Annexon, Inc. • Aim: Disease control

Last updated Jul 02, 2026 00:00 UTC